All news

Verastem prices $250 million stock offering at $8.00

Alpha Vantage · AD HOC NEWS · · AI-summarised by FinFlash

Verastem Oncology priced a $250 million stock offering of 30,937,500 common shares at $8.00 each, plus pre-funded warrants for additional shares. Proceeds will fund continued clinical development, particularly the VS-7375 program, and strengthen the company's funding position. The raise follows positive pipeline data, including a 50% confirmed response rate for VS-7375 in second-line pancreatic cancer.

Read original source

VSTM company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.